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LIM Protein Ajuba directly interacts with Replication Protein A to prevent ATR 
DNA damage response. 
 
By Sandy Wan S. Fowler 
 
Advisor: Dr. Diego Loayza 
 
Integrity of the human genome is essential for viability and proliferation of human 
cells. Intrinsic (endogenous replication stress) or extrinsic (UV, chemotherapy 
drugs) agents threaten the stability of the genome by generation of single stranded 
(ss) DNA or double stranded (ds) DNA breaks. The DNA damage 
response (DDR) pathways are conserved in evolution and constitute systems that 
perform the surveillance, signaling, and repair of the damage in the nucleus. 
Unchecked and accumulation of DNA damage can lead to deleterious effects such 
as replication fork collapse, chromosome fusion and breakage. The dysregulations 
of DNA damage response pathways are hallmarks of tumorigenesis. ATR (ataxia 
telangiectasia mutated and rad-3 related) is the protein kinase activated by ssDNA 
damage. ATR is essential for life and is recruited by ssDNA bound replication 
protein A (RPA). RPA, the major mammalian ssDNA binding complex with three 
different subunits: 70, 32, and 14, and is essential for replication, recombination 
and repair. The majority of ssDNA binding activity resides in the large subunit 
(RPA70), which directly binds to ssDNA though it’s central OB fold domains. It 
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was established that LIM protein Ajuba inhibits unscheduled ATR response, and 
associates with RPA. However, it was unclear whether the association occurred 
directly, or through additional factors. I found that the Ajuba-RPA interaction is 
direct, through the RPA70 subunit, and likely occurs in the nucleus during S phase. 
Upon replication stress, Ajuba-RPA interaction was reduced and Ajuba was 
shuttled out of the nucleus during replication stress. In addition, I mapped the 
regions that likely mediate this direct contact to the first LIM domain of Ajuba and 
the ssDNA binding OB folds of RPA70. These findings revealed additional facets 
of ATR signaling regulation, and underscored the implications of LIM proteins in 





This thesis work focuses on the characterization of the interaction between LIM 
domain protein Ajuba and OB fold protein RPA. Previously, it was shown that 
Ajuba is critical for inhibiting ATR DNA damage response and is a RPA 
interacting protein. Although LIM domains have not shown to have interacting 
partner consensus, published work showed POT1 (OB fold protein), and TRIP6 
(LIM domain protein) directly interact to prevent DNA damage response at the 
telomeres in human cells. This work explores the nature of interaction between 
Ajuba and RPA, the regulation of this interaction during unperturbed cell cycle and 
during replication stress. The findings form this work adds a new facet to the 
complex regulation of ATR activation and contributes to the establishment of an 
interacting consensus between LIM domain and OB fold proteins in repression of 
DNA damage response.  
First, whether Ajuba can be found with all the RPA subunits and co-localized with 
RPA in the nucleus would be addressed. Secondly, Ajuba depletion in an 
unsynchronized cell population led to accumulation of S phase cells, I asked if 
Ajuba nuclear localization and co-localization with RPA are cell cycle dependent. 
Thirdly, whether Ajuba-RPA interaction would be affected by replication stress 
would be examined.  
 
 vii 
To fully characterize if Ajuba directly interacts with RPA or if this interaction is 
mediated by another protein, I employed in vitro transcription coupled translation 
system with His-tag pulldown assay to address this with truncation mutants of both 
proteins. Finally, the relevance of this work and the current model developed form 
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CHAPTER 1: ATR KINASE IN DNA DAMAGE RESPONSE PATHWAY 
 
DNA DAMAGE RESPONSE AND GENOME INTEGRITY  
 
Eukaryotic genomes are constantly threatened by agents or stresses that 
compromise their stability and integrity such as UV, DNA damaging reagents 
(hydroxyurea or aphidicolin), endogenous replication stress, and telomere 
deprotection. The DNA damage response (DDR) pathways are essential to 
overcome these genotoxic stresses. The DDR signaling pathways are kinase 
cascades that can lead to cell cycle arrest, apoptosis, and DNA repair 1,2.  
There are two major DDR pathways in mammalian cells, which are activated by 
different types of DNA damage. ATR (Ataxia Telangiectasia mutated Rad-3 
related) and ATM (Ataxia Telangiectasia Mutated) are activated by single stranded 
DNA (ssDNA) breaks and double stranded DNA (dsDNA) breaks respectively 2. In 
particular, the ATR kinase has shown to be essential for cell viability 3. On the 
other hand, ATM is non-essential for cell survival 4. The ATR kinase is a master 
regulator in many essential pathways and found to be mostly active in S phase. It 
has been found to signal DNA damage response (DDR), regulate cell cycle 
progression and protect the genome from mitotic catastrophe 3,5.  
 
 2 
DDR activation is found dysregulated in early stage cancer cells to induce 
apoptosis or senescence. This prevents further proliferation and cellular 
transformation events from taking place. The suppression or mutation targeting 
members of the DDR pathway members favors cellular transformation and 
tumorigenesis in mice 6,7. Thus, the DDR pathway is essential to maintain genome 

















PHOSPHATIDYLINOSITOL 3-KINASE LIKE KINASE (PI3KK) IN DNA 
DAMAGE 
 
PI3KK family members include, in addition to PI3K itself, ATR, ATM, DNA-
PKcs (DNA Protein Kinase catalytic subunits), and mTOR (mammalian Target Of 
Rapamycin). These kinases play critical roles in regulation of the cell cycle, DNA 
damage signaling, DNA repair, and cellular metabolism in the human cell. ATR is 
the master regulator of cell cycle progression and DNA damage signaling 8. ATM 
is important for dsDNA damage signaling and repair 9. DNA-PKcs has been shown 
to be involved in dsDNA break detection and repair, along with the Ku complex 
Ku70/80 2. mTOR functions as the major mammalian cell nutrient sensor 10. 
Among the PI3KK family members, ATR, ATM, and DNA-PKcs are directly 
recruited to DNA damage sites by DNA damage sensor proteins 2. This leads to the 
activation of the kinase and subsequent activation of downstream targets.  
ATM and DNA-PKcs are activated by dsDNA damage. The Ku complex senses 
and binds to dsDNA, and recruits DNA-PKcs and PARP-1 to the damage site to 
orchestrate downstream signaling and DNA repair. ATM is recruited by the MRN 
complex (Mre11-Rad50-Nbs1) binding to dsDNA damage site. The MRN complex 
exhibits exonuclease activity that participates, along with EXO1, to the resection of 
the 5’ end, leading to the production of a 3’ ssDNA overhang. This allows ssDNA-
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binding proteins to bind to the overhang to facilitate homologous recombination 
(HR) 2 11.  
 
PIKK ATR ATM DNA-PKcs 
Recruitment ssDNA dsDNA dsDNA 
Mandatory 
partner 
ATRIP NBS1 Ku70/80 
Activator (s) TopBP1, RPA-
ssDNA 
MRN complex Ku/DNA 
Table 1. PIKKs involved in DNA damage response. 
 
Unlike ATM and DNA-PKcs, ATR is required for cell vitality. ATR knockout 
mice have been shown to be embryonic lethal 8 3. ATR is mainly activated through 
ssDNA accumulation produced by endogenous replication stress, UV irradiation, 
or treatment with DNA damaging agents such as hydroxyurea and aphidicolin 2 12 
13 14. In addition to DNA damage signaling, ATR has been shown to be involved in 
S-M phase progression, regulate origin firing, prevents replication fork collapse, 
direct cell cycle delay, and respond to mechanical stress 15-19.  
Taken all together, PIKKs are crucial components for cell survival. Mutations and 
deregulations of the pathways that inappropriately activate or inhibit these kinases 




ACTIVATION OF ATR PATHWAY 
 
In replicating cells, ATR was found to protect genome integrity through limiting 
origin firing, preventing premature exit from S phase, and inhibiting the collapse of 
the replication complex3. ATR has been found to be the master regulator for the 
intra-S and G2/M phase checkpoints in the cell cycle 5,8. It was demonstrated in 
DT40 cells (chicken lymphoma cell line) that complete depletion of the ATR 
protein results in mitosis catastrophe due to inappropriate entry into mitosis 18. The 
most extensively studied role of ATR is its activation during DNA damage events 
and the consequences thereof.  
Mutations of ATR was demonstrated to be embryonic lethal 3. Hypomorphic 
mutation of ATR has been documented to manifest in human patients as the Seckel 
Syndrome. Patients exhibit severe developmental defects, dwarfism, and 
microcephaly. In addition, mutations in downstream targets of ATR confer genome 
instability in human cells and in mouse 3,8. Also, it has recently been reported that 
an autosomal dominant mutation in ATR that elevates the occurrence of 
esophageal cancer in patients 20. This heterozygous point mutation that substitutes 
the glutamine at amino acid 2144 to arginine. Further analysis speculates that this 
mutation prevents ATR from being efficiently activated, thus allowing other 





Figure 1. General schematic depicting the activation of the ATR pathway. Circles with P 




Studies have shown that efficient ATR activation (figure 1) requires: 1) 
accumulation of ssDNA bound RPA complexes 16,21, 2) recruitment of cofactors 22, 
and 3) the presence of a replication fork 23.  
The uncoupling of the MCM helicase from DNA polymerase at the replication 
fork, as well as some instances of telomere deprotection, have been shown to 
trigger ATR activation by generating long stretches of ssDNA. RPA, the major 



































ssDNA regardless of the sequence 21. This accumulation of RPA bound ssDNA 
recruits other protein complexes necessary for efficient ATR activation at the 
damage site such as: 9-1-1 complex, TopBP1, and Rad17-RFC 3,8. RPA protects 
the ssDNA from forming secondary structures 16. More importantly, RPA presents 
itself as a “docking site” for the localization and recruitment of other proteins 16,24 
and is itself a downstream target of ATR through the RPA32 subunit 25-27. 
ATR and its mandatory partner ATRIP (ATR Interacting Protein) are recruited to 
the damage sites through direct interaction with the N-terminus of the large subunit 
of the RPA complex, RPA70 24. TopBP1 (Topoisomerase Binding Protein 1) 
possesses the AAD (ATR Activation Domain) that allows physical contact with 
ATR-ATRIP to activate ATR. It directly interacts with RPA and the 9-1-1 complex 
through its BRCT (BRCA1 C-Terminus) domains 28. The 9-1-1 (Rad9-Rad1-
Mus1) complex is structurally similar to PCNA (Proliferating Cell Nuclear 
Antigen), and functions to stabilize the dsDNA-ssDNA junction during DNA 
damage. Rad17-RFC (Replication Factor C) complex is also recruited to the 
dsDNA-ssDNA junction 8. Following this, ATR phosphorylates its downstream 
targets to halt the progression of the cell cycle, repair the DNA damage, or induce 
apoptosis.  
RPA binding to ssDNA represents a crucial step in the ATR signaling pathway. 
RPA possesses protein domains called OB folds that allows the complex to bind to 
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ssDNA with high affinity (1-5 nM range). This initial step must be strictly 
regulated to prevent unwanted ATR activating proteins’ recruitment. Another OB 
fold containing protein that prevents unwanted DDR is POT1 (protection of 
telomeres 1); it binds to the single stranded overhang at the telomeres to protect 
them from being recognized as DNA damage sites, specifically preventing 

















OLIGONUCLEOTIDE/ OLIGOSACCHARIDE BINDING (OB) FOLDS 
 
OB folds are protein domains that allow direct DNA or protein interaction. It has 
been suggested that OB fold proteins function as genome guardians in human cells 
by participating in various DNA metabolic pathways. Specifically, RPA and POT1 
both contain different numbers of OB folds that allow the proteins to bind ssDNA 
as well as interact with proteins involved in DNA replication, and damage 
signaling 30,31. POT1 possesses two N-terminal OB-folds that together constitute 
the DNA binding domain of the protein, and a third C-terminal OB-fold essential 








The general secondary structure of an OB fold is depicted in Figure 2. An OB fold 
consists of five beta strands, themselves separated by loops (L12, L3, L45) formed 
of residues that make direct contacts with the DNA. The structure may contain an 
alpha helix. The tertiary structure of OB fold proteins has been found to contribute 
to DNA binding sequence specificity 34,35. This has been shown through the 
structural determination of POT1 binding to ssDNA that the two N-terminal OB 
folds of POT1 enforce a structure to the single stranded DNA itself as a “kink”, 
which occurs through sequence specific binding to TTAGGGAATG 35,36. On the 
other hand, structural information of RPA has shown that RPA70 ssDNA binding 
OB folds exhibit a single channel unlike POT1, thus accounting for its lack of 












Replication Protein A (RPA) 
 
RPA is the major mammalian ssDNA binding protein. It is a heterotrimer; 
composed of subunits: 70, 32, and 14. As a complex, RPA can bind to 8-30 nt of 
ssDNA with a binding affinity of 2 nM with 30dT-ssDNA in vitro 37,38, although it 
has been shown that RPA shows a preference for poly-pyrimidine oligos 37. The 
expression of each subunit remains unchanged and remains a complex throughout 
the cell cycle 39. RPA is found to associate with chromatin as a trimetric complex 
40.  
Each of the subunits contains a different number of OB folds; these OB folds are 
essential for ssDNA binding and allow RPA to interact with proteins (Figure 3) 
involved in checkpoint signaling, DNA replication, and DNA repair pathways 2,41.  
 
 
Figure 3. RPA subunits domain map. RPA70 contains 4 OB folds; RPA32 contains 1 OB fold with 
multiple phosphorylation sites at its N-terminus; RPA14 contains 1 OB fold. The main function 




RPA70 contains four OB folds; the central OB folds (OB A and B) are tandem 
repeats and the major core domains that directly interact with ssDNA 42. Mutation 
or deletion of OB A or B result in a loss of function RPA 16. OB A and B alone 
exhibit low affinity for ssDNA. It has been suggested that the binding of OB A and 
B to ssDNA causes a conformation change, leading to increased affinity for 
ssDNA as a complex 37,43,44. Mutation in OB fold A has been suggested to drive 
tumorigenesis in mice 45. Either OB A or OB B alone has been shown to exhibit 
comparable affinity for ssDNA as the heterotrimer 37,46. When combined, the 
ssDNA binding affinity dramatically increased in vitro 44. In addition to direct 
ssDNA binding, OB folds A and B also participate in protein-protein interactions 
with DNA damage repair proteins, such as Rad51, WRN (Werner Syndrome 
helicase), and BLM (Bloom’s Syndrome helicase) 47. OB F is located at the N-
terminus of RPA70 and functions as the recruitment domain for RAD9, TOPBP1, 
and ATR-ATRIP, which are essential for ATR activation 24. Truncation or 
mutation in OB F confers inability to activate DDR and failure to recruit DNA 
repair proteins upon replication stress 24. In addition, mutations in OB F results in 
DNA damage agent hypersensitivity. OB C is located at the C-terminus of RPA70 




RPA32 contains one OB fold, OB D, and multiple phosphorylation sites at its N-
terminus 27,21. The phosphorylation pattern is complex, and its significance still 
poorly understood, but is intimately correlated with DNA damage and activation of 
repair pathways 16,23,48.  OB D participates in ssDNA binding and protein 
interactions 49. Although the ssDNA binding affinity of OB D alone is quite low, it 
has been suggested that the binding of OB A/B to the ssDNA facilitates the 
binding of OB D 43,50. Phosphorylation of serine/threonine residues at the N-
terminus of RPA32 has been extensively studied in yeast and mammalian cells. 
Phosphomimetic and un-phosphorylatable mutants have been generated to dissect 




Figure 4. Phosphorylation sites at the N-terminus of RPA32. Bold amino acid residues represent 
phosphorylatable sites and the kinases shown to phosphorylate the residue. (Figure adopted 




Phosphorylation of RPA32 has been proposed to influence the localization and 
DNA binding affinity of the RPA complex as well as protein-protein interactions. 
It has been shown that phosphorylation of RPA32 can be dependent on cell cycle 
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stages and DNA damage response pathway activation. During unperturbed cell 
cycle, the cyclin-CDK complexes can phosphorylate RPA32 at S23 and S29 16,25 . 
During DNA damage, RPA32 becomes hyper-phosphorylated. The hyper-
phosphorylated form of RPA32 refers to phosphorylation at residues S4, S8, S21, 
S23, and S33 26. Hyper-phosphorylated RPA32 is detected during replication stress 
and prevents RPA from associating with replication machinery 25. S33 
phosphorylation has been shown to be ATR specific in vitro and in vivo 4, this 
modification has been suggested to induce a conformational change to modulate 
RPA binding to damage sites and allow checkpoint proteins to associate with RPA. 
Thus, specific phosphorylation forms of RPA32 can present as a “read-out” for 
DDR.  
RPA14 contains one OB fold, OB E. To date, it has been shown that RPA14 









Protection of Telomeres 1 (POT1) 
 
POT1 is an OB fold containing protein that belongs to the shelterin complex. The 
shelterin complex is composed of six proteins: TRF1, TRF2, RAP1, TPP1, TIN2, 
and POT1 52. The shelterin complex functions to protect the telomeric overhangs 
from being recognized as DNA damage sites, prevents exonuclease access at the 
chromosome end, and modulates the activity of telomerase 33,52. TRF1 and TRF2 
are responsible for binding to the double stranded telomeric DNA and prevent 
ATM activation at telomeres 53. POT1 binds to the ssDNA overhang and prevents 
ATR signaling at the telomeric region, likely by preventing binding of RPA to the 
telomeric overhang 54.  
TRF1 and TRF2 have been shown to protect telomeres from ATM activation 53-55 
by binding to the dsDNA telomeric sequences and inhibiting ATM 
autophosphorylation by virtue of a direct interaction with TRF2 55. The loss of 
TRF1 or TRF2 leads to DNA damage response at telomeres, with convergence of 
DNA repair factors at telomeres and formation of telomere dysfunction induced 
foci (TIFs), and telomeric fusion between different chromosomes. TIN2 functions 
to stabilize TRF2 binding to telomeres and tethers TPP1-POT1 to the shelterin 





Figure 5. Shelterin complex at the telomeres. TRF1 and TRF2/Rap1 bind to the dsDNA junction 
of telomeric DNA. TIN1 and TPP1 tether POT1 to the shelterin complex. POT1 binds to the 




Amongst the shelterin components, POT1 is the most conserved member in 
eukaryotes, highlighting its essential function at the telomeres across species 
(Table 2) 57 .  
 
Table 2. Percent conservation (similarities) of POT1 and other proteins across different species. 
Human (Hs), mouse (Mm), chicken (Gg), frog (XI), or fission yeast (Sp). (Table adapted from 




POT1 contains three OB folds: one at the C-terminus, and two at the N-terminus. 
The C-terminal OB fold ensures direct contact between POT1 and TPP1 while the 
N-terminus OB folds bind to telomeric ssDNA TTAGGG repeats 29,56.  
 
       
Figure 6. OB folds domain map of POT1. POT1 contains two ssDNA binding OB folds at 
its N-terminus and the C-terminus OB fold has been shown to allow POT1 to tether to 
the shelterin complex via binding with TPP1.  
 
Humans possess a single POT1 gene like most vertebrates. Knockdown of POT1 in 
human cells led to accumulation of TIFs, this suggests POT1 functions to inhibit 
DDR at telomeres 29. Further, although significant telomere fusion was not 
observed, POT1 depletion led to elongated telomeres, suggesting its role in 
negatively regulating telomerase activity 29,58,59.  
On the other hand, mouse contains two POT1 genes that produce POT1a and 
POT1b. It has been shown that POT1a exhibits activity to repress ATR at the 
telomeres, while POT1b functions to modulate telomeric end processing 60. The 
ability of POT1 to block ATR activation was shown in double knock out POT1 a/b 
mouse embryonic fibroblasts, where deletion of both genes led to accumulation of 
RPA at telomeres and activation of ATR at all telomeres 61. Further, POT1 has 
OB fold OB fold OB fold 
1 634 
ssDNA binding TPP1 binding 
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been shown to modulate the nuclease activity at the chromosome ends to regulate 
end processing 62. In humans, mutations in POT1 predisposes the carrier to 
leukemia and melanomas 53. Therefore, the human POT1 gene is a tumor 
susceptibility locus.  Specifically, it has been shown that mutations in the N-
terminal OB folds of POT1 are associated by tumor incidence, and this is due to 
decrease POT1 binding affinity to the telomeres 63-66 
Our lab has shown that LIM protein TRIP6 can directly be interact with POT1 
through a yeast two-hybrid screen and immunoprecipitation from human cell 
extracts 67,68 . Specifically, TRIP6 physically comes in contact with the N-terminal 
OB folds of POT1. The depletion of TRIP6 leads to TIFs in the nucleus, but had 
modest effect on cell cycle arrest or apoptosis 68. This suggests that there are 











Lin11, Isl1, Mec3 (LIM) Proteins 
 
The LIM proteins were originally defined as a family of over 60 proteins 
containing at least one common identifiable domain called LIM domain (Lin11, 
Isl1 and Mec3). LIM proteins are conserved only in eukaryotes. Individual LIM 
domains are composed of approximately 55 amino acids with 8 highly conserved 
residues, mostly cysteine or histidine, which function to coordinate the zinc ion. In 
human, LIM proteins can contain from 1-5 LIM domains 69,70. LIM proteins are 
further subdivided into 13 families depending on the number and arrangements of 
their LIM domains. Each LIM protein contains various numbers of LIM domains, 
each LIM domain is composed of two zinc fingers. The LIM domain was 
discovered in Lin11 (C. elegans cell-lineage protein), Isl1 (Rat insulin gene 
enhancer binding protein), and Mec3 (C. elegans mechanosensory neuron 





Figure 7. LIM domains 2-D structure and conserved residues. A) Conserved residues in the LIM 
domains. B) 2-D representation of LIM domains with Zn ion binding residues. (Figure adapted 
from Kadrums et al. 2004.) 
 
 
In my work, I focused on the Zyxin family, which is characterized by three tandem 
repeats of LIM domains present in the C-terminal half of the protein. The N-
terminus is conserved among the Zyxin family members, although to a lower 
extent, and contains a nuclear export sequence responsible for dynamic trafficking 
of the protein between the nucleus and the cytoplasm 70. The Zyxin family 
members have complex cellular trafficking patterns and diverse roles, from 
transcription factors to actin associating proteins. LIM proteins are conserved only 
in eukaryotes. Zyxin family members are: Trip6, Ajuba, LPP (lipoma preferred 
partner), Migfilin, WTIP (WT1 interacting protein), LIMD1 (LIM domain 
containing protein 1), Zyxin 71.  
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Our laboratory has shown TRIP6 as a POT1 interacting partner. My work focuses 
on Ajuba, which acts similarly to TRIP6 by binding to an OB fold protein, RPA. 
TRIP6 and Ajuba have been described as scaffolding proteins that can travel 
between the cytoplasm and the nucleus to exert different functions. Both proteins 
have been shown to implicate in tumor proliferation, cancer cell migration, and 


















The AJUBA gene is located at chromosome 14 that encodes Ajuba with the 
molecular weight of 55kDa. Ajuba contains multiple phosphorylation sites at the 
PreLIM region (Uniprot) and has shown to be a substrate of multiple cell cycle 
kinases 74,75. The pre-LIM region of Ajuba lies between residues 1 and 337, and the 
three LIM domains are between position 337-397, 398-460 and 461-538. The NES 
sequence is a seven-residue sequence at positions 289-297 in the pre-LIM domain, 
which allows the protein to be shuttled between the nucleus and cytoplasm 76,77, 
Ajuba has been shown to exert different functions in different cellular 
compartments. At steady state, the protein appears to be mostly cytoplasmic as 
observed by immunofluorescence. Truncation mutants of Ajuba have shown that 
the PreLIM region localizes in the cytoplasm and the LIM domains reside in the 





Figure 8. Linear domain map of Ajuba. Ajuba contains 3 LIM domains at its C-terminus; each 
LIM domain is composed of two zinc fingers that are essential for protein-protein interaction. 
Ajuba also contains a NES (nuclear export signal) at its PreLIM region to facilitate its shuttling 
between the nucleus and cytoplasm.  
 
Ajuba has been shown to be involved in mitotic commitment, cell fate 
determination, cell-cell adhesion, and transcriptional regulation 78-81. It has been 
shown that interaction between Ajuba and Aurora A kinase (AURKA) is essential 
for AURKA activation and subsequent mitosis entry 75. Ajuba was shown to 
associate with microtubules and localize at kinetochores with Aurora B kinase to 
modulate the mitosis checkpoint 81. Further, Ajuba was shown to be a target of 
cyclin dependent kinase 2 (CDK2), and phosphorylation mutant allele of Ajuba 
conferred decrease in cell proliferation 74.  
Ajuba is found frequently truncated in esophageal squamous cell carcinoma 
(ESCC). Additional evidence has shown Ajuba mutation in head and neck small 
cell carcinoma (HNSCC) conferred sensitivity to cell cycle kinase inhibitors 82. 
1 538 
LIM 3 LIM 1 LIM 2 PreLIM NES  
  
PreLIM region LIM domains 
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These observations support a role for Ajuba as a tumor suppressor.  Our work 
suggests Ajuba suppresses ATR signaling in human cells and it is an interacting 
partner of RPA 73.  
Collectively, recent evidence published indicates that Ajuba contributes to 
inhibition of DDR, cancer cell proliferation, and cell cycle progression. This thesis 

















Thyroid receptor interacting protein 6 (Trip6) has been shown to implicate in 
various pathways. TRIP6 is located at chromosome 7 and the TRIP6 protein is 50 
kDa. TRIP6 is ubiquitously expressed in the human body 71. The general protein 
domain distribution is very similar to Ajuba: a PreLIM region at the N-terminus, a 
NES, and three LIM domains at tis C-terminus. Mutation analyses have shown that 
the LIM domains of TRIP6 localize the protein in the nucleus, while the PreLIM 
region retains the protein in the cytoplasm 83. Trip6 has been found to be involved 
in cell-cell signaling, telomere protection, and transcription regulation 71. The 
expression of TRIP6 was found upregulated in Ewing’s sarcoma and contributed to 
cell proliferation and migration 84. TRIP6 is also found highly expressed in 
precancerous lesions and in renal, colorectal, and mammary cancers 71.  
TRIP6 was found to be present at a subset of telomeres in human cells and 
associate with the Shelterin complex 67. It has been shown that TRIP6 directly 
interact with the OB folds of POT1 through its LIM domains, and protects the 
telomeres from inappropriately eliciting DDR 68. It still remains to be addressed 
how TRIP6 protects telomeres and whether it can exert similar function by 





CHAPTER 2: PROJECT OBJECTIVE/ FOCUS 
Our work has shown that association between LIM protein TRIP6 and OB fold 
protein prevents inappropriate DDR at the telomeres 68. Recently, we have been 
able to show that another Zyxin family member, LIM protein Ajuba, prevent 
unwarranted DDR in human cells 73, thus protects against apoptosis. Depletion of 
Ajuba by siRNA led to cell cycle delay and ATR activation. Ajuba was shown to 
associate with replication protein A (RPA), an OB fold containing complex, 
although it was not clear whether this interaction was direct, or mediated by other 
factors. Further, if direct interaction is shown between Ajuba and RPA complex, 
which RPA subunit mediates this contact was unknown.  
In my thesis work, I hypothesized that Ajuba protects the cell from unscheduled 
ATR signaling through direct interaction with RPA. The central focus of this 
project was to study the modality of the Ajuba-RPA association. The specific 
interest is to understand the modulation of the signaling cascade in the initiating 
step when RPA is bound to ssDNA.  
Based on the paradigm of the TRIP6-POT1 interaction, I speculated that Ajuba 
directly interacts with RPA in the nucleus. The direct interaction between Ajuba 
and RPA was probed using in vitro pulldown assays. Co-immunofluorescence and 
co-immunoprecipitation were employed to examine where this interaction takes 
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place in the cell. Further, in vitro pulldown assays using truncation mutants were 
used to identify direct protein interaction.  
My work leads to a model for ATR activation, in which Ajuba is a repressor of 
ATR signaling and RPA is a critical platform to initiate this cascade. In this 
context, the Ajuba-RPA interaction is expected to reduce during replication stress 
to allow efficient ATR activation. Additionally, the intracellular shuttling of Ajuba 
was examined under conditions of DNA replication stress.  
During DNA replication, extensive amount of ssDNA is present in the nucleus and 
can be recognized as DNA damage sites. RPA is present in the nucleus during S 
phase to bind to ssDNA at the lagging strand. I have found that Ajuba is a direct 
interacting partner of RPA. It is possible that Ajuba associates with RPA during S 
phase to prevent ATR activation. I have laid the groundwork as well to address 
whether the Ajuba-RPA interaction is specific to S phase, and to investigate 
whether Ajuba is active at every cell cycle, even though full answers to these 
questions will require further studies.  
Collectively, my work provides significance to the interaction between Ajuba and 
RPA, and leads to further characterization of this interaction during normal and 





CHAPTER 3: MATERIALS AND METHODS 
Recombinant DNA construction 
For E. coli expression Ajuba (ThermoSci, MHS6278-202807864) and Trip6 (GE 
Healthcare, MHS6278-202758539) cDNAs were PCR with primers containing 
EcoRI and Xhol sequences and ligated into pET-NT-His vector (Invitrogen). 
Ajuba-HIS-5’ (5’-GTC CAG AAT TCT GAG CGG TTA GGA GAG AAA GCC-
3’), Ajuba-HIS-3’ (5’-GTA CAC TCG AGT CAG ATA TAG TTG GCA GGG 
GG-3’), Trip6-HIS-5’ (5’-GCT ACG AAT TCT TCG GGG CCC ACC TGG CTG 
CCC-3’), Trip6-HIS-3’ (5’-GAC TTC TCG AGT CAG CAG TCA GTG GTG 
ACG GT-3’).  
For in vitro translations Ajuba and Trip6 was amplified using PCR with primers, 
Ajuba-HIS-5’ and Ajuba-HIS-3’, digested with EcoRI and Xhol, and cloned into 
pcDNA 3.1/His-B. RPA subunits were amplified with PCR using primers with 
EcoRI digestion sites and cloned into pCMVTnT vector (Promega). RPA70-5’(5’-
GTA TAT GAA TTC ATG GTC GGC CAA CTG AGC GAG-3’), RPA70-3’ (5’-
GTA TAT GAA TTC TCA CAT CAA TGC ACT TCT-3’), RPA32-5’ (5’-GTA 
TAT GAA TTC ATG TGG AAC AGT GGA TTC GAA-3’), RPA32-3’ (5’-GTA 
TAT GAA TTC TTA TTC TGC ATC TGT GGA-3’), RPA14-5’ (5’-GTA TAT 
GAA TTC ATG GTG GAC ATG ATG GAC TTG-3). RPA14-3’ (5’-GTA TAT 
GAA TTC TCA ATC ATG TTG CAC AAT-3’). POT1 was amplified with PCR 
 
 29 
with primers containing Xhol digestion sequence into pCMVTnT vector. POT1-5’ 
(5’-GTA TCC TCG AGA TGT CTT TGG TTC CAG CAA C-3’), POT1-3’ (5’-
GTA TCC TCG AGT TAG ATT ACA TCT TC TGCA AC-3’).  
Ajuba truncation mutants were produced using PCR with primers containing 
EcoRI and Xhol digestion sites into pcDNA3.1-B/NT-His vector (Invitrogen, 
product #). LIM-HIS, aa 337-538: LIM-HIS-5’ (5’-CAC ACG AAT TCT GGC 
ACC TGT ATC AAG TGC AAC-3’), Ajuba-HIS-3’. PreLIM-HIS, aa 1-337: 
Ajuba-HIS-5’, PreLIM-HIS-3’ (5’-GTA CAC CTC GAG TCA GCC GAA GTA 
GTC CTC CCT GGC-3’). PreLIM/LIM1-HIS, aa 1-397: Ajuba-HIS-5’, 
PreLIM/LIM1-HIS-3’ (5’-GTA CAC CTC GAG TCA CTG AAA CCC TGA 
AAA CAG-3’). PreLIM/LIM12-HIS, aa 1-460: Ajuba-HIS-5’, PreLIM/LIM1+2-
HIS-3’ (5’-GTA CAC CTC GAG TCA AGC ATA ATT TTT GTG GTA-3’).  
RPA70 truncation mutants were produced using PCR with primers containing 
EcoRI digestion sequences into pCMVTnT vector. RPA70-OBABC, aa 169-612: 
OBABC-5’ (5’-CAC AAC GAA TTC ATG GGT CCC AGC CTG TCA CAC-3’), 
RPA70-3’. RPA70-OBF, aa 1-169: RPA70-5’, OBF-3’ (5’-CAC AAC GAA TTC 
TCA TGC AGC TTT TCC AAA TGT CTT-3’). RPA70-OBB+C, aa 302-612: 
OBBC-5’ (5’-CAC AAC GAA TTC ATG GAT TTC ACG GGG ATT GAT GAC-
3’), RPA70-3’. RPA70-OBF+A, aa 1-169: RPA70-5’, OBF+A-3’ (5’-CAC AAC 
GAA TTC TCA GAA ATC AAA CTG AAC CGT-3’). RPA70-OB½ABC, aa 
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234-612: OB½ABC-5’ (5’-CAC AAC GAA TTC ATG CGA GCT ACA GCT 
TTC AAT-3’), RPA70-3’. Clones were confirmed by sequencing.   
Expression of recombinant proteins in E. coli. 
Ajuba-His and Trip6-His plasmids were transformed in BL21 StarTM (DE3) cells 
(Invitrogen, C6010-03) and grown in 5ml LB with ampicillin (100mg/ml) (Sigma, 
A-9518) overnight in cell shaker at 37̊C. Inoculated 1L of LB with ampicillin next 
day with overnight culture and grown to cell density OD600 0.5. IPTG (Sigma, 
I5502-5G) was added to the culture to achieve final concentration of 0.5mM and 
incubated in shaker for three hours at 37C or overnight at 28C. 
Affinity purification of His-tagged proteins 
Ni-NTA beads (BioRad, 1560123) were washed with dH2O and with lysis buffer 
(50mM Na2HPO4, 300mM NaCl) twice. Beads were transferred into a small 
column and kept at 4C. Bacteria pellet was collected by centrifugation and lysed 
with lysis buffer with protease inhibitor cocktail (Roche). Cell lysate was slowly 
transferred into the column and washed with wash buffer (50mM Na2HPO4, 
300mM NaCl). His-tagged proteins were eluted with elution buffers (50mM 
Na2HPO4, 300mM NaCl, 100-150mM imidazole) containing concentration 
gradient of imidazole (concentrations). Fractions of the elution were collected and 




Silver staining was performed according to manufacturer instructions (BioRad).  
Cell culture and drug treatments 
HTC75 and IMR90 (human diploid lung fibroblasts) (ATCC® CCL-186™) cell 
lines were employed. HTC75 is a derivative of HT1080 (human fibrosarcoma). 
IMR90 was used at population doubling 30. HTC75 cells were cultured in DMEM 
(Cellgro, 10-017-CV) with 10% BCS (HyClone, SH30072.03), 1% penicillin and 
streptomycin (Cellgro, 30-002-CI) and 1% L-glutamine (Gibco, 25030-081). 
IMR90 cells were cultured in DMEM with 20% FBS (ClonTech, 631106), and 1% 
penicillin and streptomycin. Both cell lines were grown in cell culture incubator at 
37̊C with 5% bone dry CO2.  
Hydroxyurea was added to the media to achieve a final concentration of 2mM. 
Cells were collected after 24 hours of treatment. Double thymidine block was 
performed by adding final concentration of 2mM thymidine to the media. Cells 
were synchronized for 18 hours and was rinsed with media to release for 10 hours. 
Thymidine was added the second time for 18 hours. Cells were rinsed with media 
to release for hours indicated. Cell cycle profile was accessed by FACS. 
Cells were grown on glass cover slips to 70% confluency and leptomycin B was 
added for a final concentration of 10ng/ml. Cells were incubated for 3 hours at 37 




Cells were collected by trypsinization and pelleted after centrifugation at 1500xg 
for 10mins at 4°C. Cell pellets were washed with PBS (pH= 8.0) twice. 0.5ml of 
lysis buffer (50 mM Tris-HCl pH 7.4/1% Triton X-100/ 0.1% SDS/150 mM 
NaCl/1 mM EDTA/1 mM DTT/1mM PMSF, with protease inhibitor cocktail 
(Invitrogen)). Nuclear proteins were extracted by addition of 25ul (5M stock) of 
NaCl and incubated on ice for 20 minutes. Lysates were diluted by adding 500ul of 
ice-cold dH2O. The samples were subjected to centrifugation at 18,000xg for 10 
minutes (4°C). The supernatants were collected. Protein G Sepharose beads were 
blocked with BSA and E. coli DNA for 3 ½ hours at 4°C. At the same time, 5ul of 
antibody targeting the protein of interest was added to 200ul of whole cell lysate 
and incubated at 4°C for 3 ½ hours. 32ul of blocked beads was added to each 
sample and incubated for 30 minutes at 4°C. Beads were washed five times with 
1ml of ice cold lysis buffer without protease inhibitor. 50ul of loading buffer was 
added to each sample and subjected to Western blot analysis.  
Co-immunofluorescence 
HTC75 and IMR90 cells were grown on glass coverslips and were washed twice 
with PBS at room temperature. Fixed cells with 2% formaldehyde in PBS for 10 
minutes at room temperature. Washed cells twice with PBS and permeabilized 
with 0.5% NP-40 in PBS for 10 minutes. Washed cells with PBS twice. Blocked 
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with PBG for 30 minutes at RT. Added primary antibody diluted in PBG (Ajuba 
1:2500, RPA70 1:2500) and stored at 4C overnight. Washed with PBG three times 
and incubated with fluorescent secondary antibody diluted in PBG for 45 minutes 
at RT (Anti-rabbit 1:1000, Anti-mouse 1:1000). Washed with PBG twice and 
incubated the coverslip with DAPI in PBG at 100 ng/ml. Coverslips were mounted 
on microscope slides with embedding media and sealed with nail polish.  
FACS (Fluorescent Activated Cell Sorting) 
Cells were collected and fixed in PBS-EDTA and ethanol. Staining solution 
(Triton X-100, RNase A, propidium iodide) was used to stain cells.  
In vitro co-translation 
1ug of Ajuba/Ajuba mutant plasmid and 1ug of RPA subunit/RPA70/RPA70 
mutant plasmid were added into the same reaction. The in vitro translation protocol 
was performed as described in manual from manufacturer (Promega, TNT© T7 
Coupled Reticulocyte Lysate System, L4610) with 35S-methionine (PerkinElmer).  
His-tag affinity pulldown 
Ni-NTA beads were washed with dH2O and TBST (pH=8.0, 0.01% Tween-20). 
The beads were blocked with 2% BSA (Sigma) (10mg/ml) in TBST for 2 hours at 
room temperature. 20ul of blocked beads were added to each sample and incubated 
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at room temperature for 30 minutes. Beads were washed with 100ul TBST six 
times and loading buffer was added directly to beads.  
Autoradiography 
SDS-PAGE gels were dried with BioRad Gel Dryer at 80°C for two hours. The 
dried gels were put into a phosphor storage cassette overnight (Amersham). The 
storage screen was visualized with Phosphor imager (Typhoon 9410).  
Autoradiography quantitation 
Radioactive signals were measured using ImageQ 2D analysis software. The 
signals were normalized to the number of methionine in each protein and the signal 
of His-tagged proteins. We assume that each pulldown constitutes a 1:1 ratio of 
Ajuba:RPA subunit. Pulldown efficiencies were calculation using the ratio of 
expected protein pulldown signal to the observed signal. Graphs and statistical 
significance were produced and calculated using Prism Graph Pad software.  
Cell fractionation 
Cells were collected and washed with PBS and washed twice in buffer A (10mM 
HEPES, pH 7.9, 10mM KCl, 1.5 mM MgCl2, 0.34M sucrose, 10% glycerol, 1mM 
DTT, and protease inhibitor cocktail) and centrifuged for 14000xg for 10 minutes 
at 4C. The supernatant was collected as the cytoplasmic proteins (CP). The pellet 
was resuspended with buffer B (3mM EDTA, 0.2 mM EGTA, 1mM DTT, and 
 
 35 
protease inhibitor cocktail) and centrifuged for 5 minutes at 1700xg, 4C. The 
supernatant (soluble nucleoplasm, NP) and the pellet (chromatin bound, CB) were 
collected.  
To obtain the soluble chromatin fraction, the nuclei pellet was resuspended with 
buffer A with micrococcal nuclease and 1mM CaCl2 and incubated at 37C for 1 
minute, then centrifuged for 5 minutes at 1700xg, 4C.  
siRNA transfection 
HTC75 cells were grown in complete DMEM media without antibiotics 24 hours 
prior to transfection. Lipofectamine reagent (Invitrogen) was used to transfect 
Ajuba siRNA #3 (5’- GCAGCUGAGUGAUGAGGAAUU-3’) and incubated with 
cells for 48 hours at 37°C before collection. 
Western blot analysis 
Samples were prepared as described above and 4x loading buffer was added to 
each sample to run on 10% SDS PAGE gels at 120V. Gels were transferred onto 








CHAPTER 4: CHARACTERIZING AJUBA’S INTERACTION WITH 
REPLICATION PROTEIN A IN VIVO 
Introduction 
The ATR pathway is pivotal to signal DNA damage to orchestrate cell cycle delay 
and damage repair. Cells rely on this pathway to maintain genome integrity and to 
prevent the passage of erroneous genetic information. The ATR response is a 
signaling cascade and each step has to be precisely coordinated to ensure the full 
execution of the downstream effects. The initial step of ATR activation is the 
binding of RPA to the ssDNA region. This accumulation of RPA-ssDNA further 
recruits other components such as the 9-1-1 complex, TopBP1, and ATR-ATRIP to 
elicit the DDR signaling pathway.  Upon DNA damage ATR is 
autophosphorylated 85, and Chk1 is phosphorylated at S296 and T345 86, RPA32 is 
phosphorylated on residues T21 and S33 by ATR 25. This signaling cascade would 
result in DNA damage repair, cell cycle delay, and apoptosis 3,8.  
Due to the dire consequences from activating the ATR pathway, it is necessary for 
the cell to activate this pathway only when needed. The cell cannot sustain ATR 
activation during every S phase, because this will ultimately put its proliferation 
potential to a halt. Our laboratory has published observations documenting the 
critical interactions between LIM proteins (Ajuba, Trip6) and OB fold proteins 
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(RPA, POT1) in maintaining genome integrity 68,73. In particular, Ajuba was found 
to suppress inappropriate DNA damage response during normal cell cycle. 
 
 
Figure 9. Ajuba co-immunoprecipitates with RPA32 and depletion of Ajuba leads to RPA32 
phosphorylation. A) co-immunoprecipitation of Ajuba and RPA32 in HTC75 (human 
fibrosarcoma) and IMR90. B) RPA32 (human diploid fibroblasts) phosphorylation at T21 upon 






Figure 10. Immunofluorescence of RPA32 S33-P in unsynchronized HTC75 cells. (Top) Cells 
treated with siRNA Ajuba. (Bottom) Cells treated with GFP siRNA.  
 
 
Knockdown of Ajuba resulted in severe reduction in cell viability and cell cycle 
delay, with enrichment for cells in S phase 73. Further, Ajuba was found to 
immunoprecipitate with RPA32 in unperturbed human cells and down regulation 
of Ajuba resulted in RPA32 phosphorylation (Figures 9 and 10).  Induction of 
DNA damage induced foci was observed after Ajuba depletion using 
immunofluorescence (Figure 10). In this experiment, RPA32 S33-phospho foci 
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53BP1foci, and Chk1 phosphorylation were detected upon Ajuba depletion as well 
73. Thus, Ajuba plays a key role in DDR regulation and we hypothesized that Ajuba 
exerts its function through interacting with RPA32. Hence, we sought to explore 
the relationship between RPA and Ajuba. 
We have established a model in which Ajuba negatively regulates the ATR 
pathway through interaction with RPA. We probed the interaction between the two 
proteins in vivo by asking whether Ajuba can be found interacting with the RPA 
complex in the cell and if this is taking place inside the nucleus. In addition, we 
aimed to elucidate whether Ajuba and RPA interact more frequently during DNA 
replication. We also sought to investigate the effects of DNA damage on Ajuba-
RPA relationship: whether the two proteins remain to associate with each other and 













AJUBA INTERACTS WITH THE RPA COMPLEX 
To address the relationship between Ajuba and RPA, we asked if Ajuba interacts 
with the whole RPA complex or just individual RPA subunits in the cell. We 
performed immunoprecipitation of Ajuba using antibodies against the three RPA 
subunits, followed by Western blot detection for Ajuba. Here, two cell lines were 
employed: HTC75 (human fibrosarcoma) and IMR90 (human diploid fibroblasts). 
HTC75 is a derivative of HT1080 cell line (human fibrosarcoma) and harbors no 
known mutation in ATR mediated DNA damage response proteins. IMR90 is used 
to investigate the whether the Ajuba-RPA interaction takes place in an 









Figure 11. Ajuba is found immunoprecipitated with the RPA heterotrimer in HTC75 (human 
fibrosarcoma) cells. (Top) Co-immunoprecipitation of Ajuba by RPA subunits. (Bottom) Co-




Ajuba was found to immunoprecipitate with all three subunits of the RPA complex 
in untreated HTC75 cells (Figure 11). We observed that only a small amount of 
Ajuba immunoprecipitated with each of the RPA subunits compared to the amount 
in total lysate (5% input), estimated at 2-5% of total Ajuba in my blots. This 
suggests that Ajuba interacts with the whole RPA complex in cells, but that the 
pool of Ajuba in association with RPA constitutes a minor fraction.   
Further, we looked if Ajuba is co-localized with RPA in the nucleus by co-
immunofluorescence in unsynchronized cells. We observed a sub-population of 
cells displayed co-localized signals of Ajuba and RPA70 inside the nucleus in 
HTC75 and IMR90 cells (Fig. 12). In the cells that showed a detectable signal for 
Ajuba in the nucleus, we found 1-3 foci of co-localization between Ajuba and 






Figure 12. Co-immunofluorescence of Ajuba and RPA70 in unsynchronized HTC75 (human 




HTC75 cells treated with leptomycin B, which retains proteins inside the nucleus 
due to inhibition of exportin 1-dependent nuclear export 87, showed increase 
colocalization events of Ajuba and RPA70 (Figure 13). This suggests that Ajuba 
colocalizes with RPA70 in the nucleus in cancer cells as well as primary 
untransformed cells. In addition, forced retention of Ajuba in the nucleus enhances 
this event in cells.  
 
HTC75 









Figure 13. Sequestering Ajuba nuclear export increases co-localization with RPA70. (Top) Co-
immunofluorescence of Ajuba and RPA70 in unsynchronized HTC75 cells treated with 
Leptomycin B for 3 hours (n=2). (Bottom) Quantitation of cells exhibited >3 foci of Ajuba and 
RPA70 colocalization in unsynchronized cells (UT) and cells treated with leptomycin B (+ Lept. 
B). (n= 1) 
 
Although leptomycin B treatment did increase Ajuba-RPA70 colocalization event 
(from 20% in untreated cells to 50% in leptomycin B treated cells), there was a 






HTC75 DAPI Ajuba RPA70 Merge Merge + DAPI 
 
 44 
explained by regulation of the localization of Ajuba in the nucleus, for instance by 
cell cycle checkpoints.  
S phase is the only phase in the cell cycle that implicates production of ssDNA in 
the nucleus that requires the binding of RPA, we hypothesized that colocalization 
with Ajuba would be detectable mostly during that period. Possibly, interaction 
with RPA would occur during this vulnerable time of DNA replication to prevent 
inappropriate or excessive ATR activation. To clarify this point, cells were 
synchronized to G1/S border with double thymidine block 88. Thymidine was 
washed off with PBS and replaced with fresh media without thymidine. 
Subsequently, cells were released into S phase. Importantly, it was shown that the 
majority of RPA exists in the nucleoplasmic fraction, thus washing the cells with 
Triton-X 100 prior to fixing would extract the majority of nucleoplasmic RPA and 
leaving behind the chromatin bound RPA fraction in the nucleus. Therefore, cells 
were collected at 2-hour time points, washed with Triton-X 100, and subjected to 
co-immunofluorescence with Ajuba and RPA70 antibodies to examine whether the 
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Figure 14. Immunofluorescence of Ajuba nuclear localization during S phase. HTC75 cells were 
synchronized to G1/S border with double thymidine block and released into S phase. (Top) 
Increase of Ajuba nuclear localization during S phase. Cells were collected at the time indicated 
and washed with Triton-X 100 twice to extract nucleoplasmic proteins. Ajuba (green), nuclei 
(DAPI, blue). Scale bar indicates 10um. (Bottom) Quantitation of cells exhibited high Ajuba 




As shown in Figure 14, strong Ajuba signal was observed in only in 33.02% of 
unsynchronized HTC75 cells. When the cells were synchronized with double 
thymidine (dT) block, at 0 hour, the percentage of cells that exhibited clear Ajuba 
signals in the nucleus increased to 35.77%. Upon release from the dT block, strong 
nuclear Ajuba signals were found in 54.41% and 68.93% of cells after 2 and 4 
hours release, respectively. Ajuba’s presence in the nucleus began to reduce at 6 
hours after dT release, with 46.8% of cells showed nuclear Ajuba signals. Upon 
analysis, cells that exhibited strong Ajuba nuclear signal at 4 hours after released 
from dT block is significantly more abundant compared to unsynchronized cell 
population. This indicates that Ajuba’s nuclear import or retention in the nucleus is 





























Figure 15. Co-Immunofluorescence of Ajuba and RPA70 in the nucleus during S phase. HTC75 
cells were synchronized to G1/S border with double thymidine block and released into S phase. 
(Top) Increase of Ajuba-RPA70 co-localization during S phase. Cells were collected at the time 
indicated and washed with Triton-X 100 twice to extract nucleoplasmic proteins. Ajuba (green), 
RPA70 (red), nuclei (DAPI, blue). Scale bar indicates 10um. (Bottom) Quantitation of cells 
exhibited >3 foci of Ajuba-RPA70 signal in the nucleus at each indicated time point. 
*Experiment was done with the assistance of Baila Schochet.  
 
 
We probed for Ajuba-RPA interaction in dT block and release HTC75 cells.   
 Quantitation of cells that exhibited >3 foci of Ajuba-RPA70 co-localization at 
each cell cycle release time point after synchronization is depicted in the bottom 
panel of Figure 15.   
Figure 15 shows an increase of co-localization events occur in HTC75 cells from 2 
hours to 6 hours (Table 3), with the 4 hours time-point exhibiting the highest 
percentage of cells with Ajuba-RPA foci in the nucleus (61.94%). 27.48% of 
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unsynchronized (untreated) cells showed 3< co-localized foci, which is comparable 
to the percentage of cells at 6 hours time-point (27.44%). Interestingly, at 0 hour, 
similar percentage of cells (17.65%) was found compared to unsynchronized 
population (27.48%). In addition, 34.32% of cells from 2 hours release from dT 
block showed co-localization signals. At 4 hours release, 54.83% of cells showed 
co-localized foci. This suggests that Ajuba-RPA interaction is strongly enhanced 
during mid-S phase. This data complements figure 14 that show gradual increase 
of Ajuba accumulated in the nucleus.   
PCNA (Proliferating Cell Nuclear Antigen) is the sliding clamp that functions at 
the replication fork to tether DNA polymerase along the template DNA 89. RPA is 
recruited to replication forks to bind to ssDNA and has been shown to colocalize 
with newly synthesized DNA and PCNA 90. We speculate that Ajuba may be 
protecting the replication fork through local inhibition of ATR activation. Co-





Figure 16. Ajuba can be found at some replication sites. Co-immunofluorescence of PCNA and 
Ajuba in synchronized HTC75 cells with double thymidine block and release. Cells were 
collected at the time indicated and washed with Triton-X 100 twice to extract nucleoplasmic 
proteins. Ajuba (green), PCNA (red), nuclei (DAPI, blue). Scale bar indicates 10um. 
 
 
Figure 16 shows HTC75 cells that are synchronized with dT block and release. At 
0 hours and in unsynchronized cells, low levels of Ajuba and PCNA are found in 
the nucleus. Upon release into S phase, an increase of nuclear Ajuba signals is 
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Ajuba is observed to be present at a subset of replication sites. This suggests that 
Ajuba may exert its function to repress local ATR activation.  
Collectively, we found that Ajuba can be found with the RPA trimeric complex 
and partially colocalizes with RPA70 in the nucleus. This colocalization event in 
the nucleus was enhanced with leptomycin B treatment. In addition, cell nuclei 
exhibited strong Ajuba signals upon dT block and release at 4 hours (mid-S phase 
cells) compared to untreated cells. The observation of increase Ajuba nuclear 
localization during S phase was complemented with the concomitant increase of 
Ajuba-RPA70 colocalization signals. Further, Ajuba is found to be present at a 
subset of replication sites. These data suggest that Ajuba may exert its function 
during DNA replication at a selected population of replication sites to inhibit local 











AJUBA-RPA INTERACTION DURING DNA DAMAGE 
The interaction between Ajuba and RPA sparked the question whether this 
interaction is important during replication stress. In previous publication, the 
knockdown of Ajuba led to inappropriate unleashing of DDR, cell cycle delay, and 
apoptosis in human cells 73. This introduced Ajuba as a negative regulator in the 
DDR pathway. Hydroxyurea (HU) is a ribonucleotide reductase inhibitor that halts 
S phase progression by depleting the nucleotide pool inside the cell 91. Treatment 
with HU arrests cells at G1/S phases due to stalled replication forks and ssDNA 
accumulation in the nucleus 92. Here, we employed HU to explore how Ajuba-RPA 
relationship is affected in cells when confronted with DNA replication stress. 
Ajuba possesses a NES, which enables it’s shuttling from the nucleus. We aim to 
investigate if the shuttling of Ajuba is triggered by replication stress using cell 


















   
Figure 17. Ajuba-RPA interaction reduces upon replication stress. A) Co-immunoprecipitation of 
Ajuba and RPA32 in HTC75 and IMR90 cells. Cells were treated with 2mM of hydroxyurea (HU) 
for 24 hours. Double thymidine block synchronized the cells to S phase. 5% of total lysate was 
loaded as input. B) FACS analysis of cells in panel A. C) Co-immunoprecipitation of Ajuba and 




We performed co-immunoprecipitation in HTC75 and IMR90 cells that were 
unperturbed/ untreated, or treated with 2mM HU for 24 hours, or dT blocked and 
released into S phase. Figure 17A shows RPA32 can be immunoprecipitated by 
Ajuba in both untreated and S phase cells. Ajuba-RPA32 interaction is 
significantly reduced in cells treated with 2mM HU. FACS analysis (Figure 17B) 
shows majority (64% and 63% for HTC75 and IMR90 cells, respectively) of 
untreated cells are in G1 phase. 76.7% and 73% of the cell populations were 
synchronized to S phase with double thymidine block and release. Treatment with 
2mM with HU arrested 41% (HTC75) and 44% (IMR90) of the cells in S phase. 











with HU (Figure 17C). Ajuba’s association with RPA complex in S phase cells but 
not in cells with replication stress argue Ajuba-RPA interaction is maintained in 
proliferating unperturbed cells. Enforced DDR through treatment with HU led to 
the interruption of this interaction. We propose that dissociation of Ajuba-RPA is 
essential for full activation of ATR response.  
Moreover, this data suggests Ajuba interacts with RPA during S phase and DNA 
damage in the cell disrupts this interaction. This dissociation does not appear to be 
a mere consequence of cells being in S phase, since synchronizing cells in S phase 













AJUBA IS TRANSLOCATED OUT OF THE NUCLEUS UPON DNA DAMAGE 
Ajuba has been shown to shuttle between the nucleus and the cytoplasm to carry 
out its various functions 78. I am interested in elucidating whether Ajuba is still 
present in the nucleus during DNA damage. I employed co-immunofluorescence to 
probe for RPA70 and Ajuba’s presence in the nucleus with and without the 





Figure 18. Ajuba nuclear signals reduced after hydroxyurea treatment. Co-immunofluorescence 
of Ajuba and RPA70 in HTC75 (top) and IMR90 (bottom) cells treated with and without HU. Cells 
were treated with 2mM HU for 24 hours. Scale bar indicates 10um.  
 














We found that the amount of Ajuba in the nucleus is significantly reduced upon 
HU treatment in HTC75 and IMR90 cells (Figure 18). We observe punctate foci of 
RPA70 in HU treated cells, indicating activation of DDR 93,94. Quantitation of cells 
that exhibit nuclear Ajuba signals with and without HU treatment is depicted in 
Table 3. We found that both cell lines exhibit similar percentage of cells containing 
nuclear Ajuba signals in an unsynchronized population. HU treatment led to a 37% 
decrease of nuclear Ajuba signal in cell nuclei in both cell types. This suggests that 
the absence of Ajuba in the nucleus is important for DDR in cancerous and non-
transformed cell types.  
 
 - HU + HU 
Ajuba signal 
in the nucleus 
- + - + 
HTC75 46.92% 53.08% 84.31% 15.69% 
IMR90 46.36% 53.63% 84.21% 15.79% 
 Table 3. Percentage of cells exhibit Ajuba signal in the nucleus with or without treatment of HU 




This led to the speculation that Ajuba is shuttled out of the nucleus during DDR. 
To address this point, we performed cell fractionation to probe for Ajuba in 





Figure 19. Chromatin bound Ajuba is reduced after hydroxyurea treatment. (Left) untreated 
cells. (Right) cells were treated with hydroxyurea (2mM) for 24 hours. CP: cytoplasmic, NP: 






We found that in untreated cells, small amounts of Ajuba and RPA32 are present in 
the chromatin bound (CB) fraction at very low amounts. We note that Ajuba 
appears as a lower molecular weight band in the chromatin fraction. Presently, we 
have not characterized this discrepancy, and cannot distinguish the presence of a 
specific Ajuba isoform in the nucleus (isoform 3 has a compatible molecular 
weight as per the NCBI website) from a non-specific signal. In addition, this lower 
molecular weight (MW) band could represent the unphosphorylated species of 
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Ajuba 74. More work is required to confirm the presence of Ajuba on the chromatin 
using this assay. The nucleoplasm fraction shows a marked higher amount of 
RPA32 compared to the chromatin fraction, and Ajuba is not detected in the NP. It 
has been shown that PARP supports DNA replication, DNA repair, as well as 
chromatin remodeling 95,96, thus PARP (polyADP ribose polymerase) is found at 
the CB fraction without significant cleavage in untreated cells. 
After treatment with HU, most of RPA32 is found in the chromatin bound fraction 
as expected due to formation of extensive ssDNA in the nucleus. Ajuba is not 
found in the chromatin bound fraction, and the lower MW band increases in the 
cytoplasmic fraction (Figure 8). PARP cleavage is apparent in the chromatin bound 
fraction after HU treatment indicative of apoptosis 97,98. Although preliminary, this 
data suggest that Ajuba is present on the chromatin during unperturbed cell cycle 
and transported out of the nucleus during DDR. It is possible that the low amount 
of Ajuba seen in the chromatin fraction could be retained there through interaction 
with RPA, and replication stress (HU) reduced the Ajuba-RPA association, leading 






CHAPTER SUMMARY/ DISCUSSION: 
Here, I presented data of Ajuba’s interaction with the RPA complex in vivo during 
unperturbed cell cycle and replication stress. The two proteins co-localized within 
the nucleus in a subset of unsynchronized HTC75 cells, cell cycle synchronization 
by dT block and release led to a significant increase of co-localization events 
compared to unsynchronized cells (figures 12, 13, 15). The percentage of 
synchronized cells that showed strong nuclear Ajuba signals complemented with 
the percentage of cells that exhibited Ajuba-RPA70 colocalization foci (Figures 14 
& 15). In addition, Ajuba is found to colocalize at a subset of replication sites 
(figure 16). These data suggest that nuclear entry of Ajuba and Ajuba-RPA 
interaction are upregulated in S phase, implicating Ajuba’s function to inhibit ATR 
response during DNA replication.  
We found that Ajuba-RPA interaction is reduced after HU treatment by Western 
blot analysis (Figure 17). We did not observe detectable Ajuba signal inside the 
nucleus upon HU treatment (figure 18, table 4). Further, cell fractionation data 
argues that Ajuba is shuttled out of the nucleus under replicative stress conditions 
(figure 19), underscoring its critical role in preventing inappropriate ATR 
activation through interaction with the RPA complex. The reduction of the Ajuba-
RPA interaction within the nucleus and the shuttling of Ajuba from the nucleus 
could be part of ATR activation during replication stress. These results suggest the 
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CHAPTER 5: CHARACTERIZING THE INTERACTION BETWEEN AJUBA 
AND REPLICATION PROTEIN A IN VITRO 
Introduction: 
 The RPA complex is a heterotrimer: RPA70, RPA32, and RPA14. Each 
subunit has been shown to interact with a list of different proteins though its OB 
folds8. RPA70 possesses four OB folds: F, A, B, and C21. Studies have shown that 
OB folds A and B are the main DNA binding domains, with OB fold A exhibiting 
the highest affinity for ssDNA. In addition, other studies have shown OB fold A 
can also interact with proteins involved in DNA metabolism such as Werner 
syndrome helicase (WRN)47, Bloom syndrome helicase (BLM)47,99, and Xeroderma 
Pigmentosum Group A-Complementing Protein (XPA)100. OB fold F has been 
shown to function as a docking site for numerous proteins involved in check point 
activation and DDR8,24. Finally, OB fold C facilitates in subunit interaction. 
RPA32 contains only one OB fold that is involved in subunit interaction with 
RPA70. RPA14 contains one OB fold that functions in subunit interaction21. 
 The LIM protein Ajuba possesses a pre-LIM region at the N-terminus and 
three LIM domains at the C-terminus101. Published experiments have shown that 
the LIM domains of Ajuba are important for protein-protein interactions81. The 
pre-LIM domain of Ajuba is proline rich and includes a NES. The three LIM 
domains are tandem repeats and each LIM domain is consists of two zinc fingers70. 
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The role of Ajuba in maintenance of genome integrity was shown in our previous 
work 73 which proposed a model that Ajuba is implicated in the suppression of 
ATR signaling through interaction with RPA (Figure 20).  
 
 
Figure 20. Model of Ajuba’s function in preventing unscheduled DDR. It is not known if Ajuba 
directly interacts with RPA. Figure adapted from Kalan S. et al.  
 
To further investigate the relationship between RPA and Ajuba, we sought to 
elucidate the nature of interaction between the two proteins. The co-
immunoprecipitation shown in Figures 11 and 17 do not address whether the RPA-
Ajuba interaction is through direct contacts, or mediated by other factors. 
Therefore, I sought to determine whether the interaction between Ajuba and RPA 
complex is direct. To address this question, I employed two approaches: first, to 




FIGURE 13: AJUBA ASSOCIATES WITH RPA IN HTC75 AND IMR90 CELLS.  
(A) West rnblot probed ith a total anti-RPA32 antibody after Immunoprecipitation with 
a commercial anti-Ajuba antibody (com.) or anti-peptide serum from IMR90 or HTC75 
extracts as indicat d. Left panel: total lysates (input) for each cell line, and the pre-
immune serum (PI) used as a control for the Immunoprecipitation. (B) Westernblot for 
RPA32-p-Thr21 in both HTC75 and IMR90 Ajuba-depleted cells. A non-specific band is 
marked by a *. Total RPA32 Levels are shown at the bottom. (C) Model for the role of 
Ajuba in repression of ATR. The “?” indicates that the interaction between Ajuba and 
RPA could be direct or indirect. See text for details.  
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rabbit reticulocyte in vitro transcription/translation system for Ajuba and RPA 
subunits for pull downs. Although only the second strategy proved informative, I 




















Ajuba and TRIP6 were cloned into pET/NT-His vector under the lac promoter so 
the 6xHis tag would fuse to the N-terminal of the proteins. Protein production was 
induced by adding 2mM IPTG and incubated at 28C overnight. Bacterial cultures 
were collected and lysed. The whole cell lysate was incubated with Ni2+-NTA 
beads, washed with lysis buffer and buffer containing 10-30mM of imidazole. 
Finally, the His tagged proteins that are bound to nickel beads was be eluted with 
elution buffer containing high concentration of imidazole (100-150mM).  
 
Production and purification of recombinant LIM proteins from E. coli 
To address direct interaction between OB fold and LIM proteins, we first 
attempted to purify each target protein by affinity chromatography. Each target 
gene was cloned into IPTG inducible promoter with peptide tags. For LIM 
proteins, Ajuba and Trip6 were cloned into pET-NT His vector. The constructs 
were transformed into BL21 cells and production of recombinant proteins was 
induced with the addition of 2mM IPTG overnight at 28 degrees Celsius. To 
confirm the production of His-tagged proteins, whole cell lysates were prepared 
and analyzed with Western blot (Figures 21).  





Figure 21. Whole cell lysate of BL21 cells overexpressing Ajuba-His (A) and TRIP6-His (B). 
 
 
Two liters of BL21 cells were lysed after induction with IPTG overnight and 
incubated with 5ml of 50% slurry Ni2+-NTA beads for 3 hours at 4 degrees Celsius 
102.  The beads were transferred into a column in cold room (4 °C), and washed 
with lysis buffer and non-denaturing buffers containing increasing concentrations 
of imidazole to elude the bound proteins. Fractions were collected for each wash 
and elution, and were analyzed with Western blot and silver staining.  
As shown in Figure 22, Ajuba-His was eluted with high yield in the wash fractions 
1 and 2 (25mM imidazole). Unfortunately the purity of the fractions containing 
high Ajuba concentrations was not adequate for further use. Additional attempts 
were made employing lower concentrations of imidazole in the wash buffer; this 
also led to impurities in the final elution fractions. Identical protocol was 
performed with TRIP6-His yielding slightly better results (Figure 23). We carried 
TRIP6 with this protocol to use as a LIM protein control for Ajuba, as well as 

















Figure 22. Purification of His-Ajuba with affinity chromatography using Ni-NTA beads. 
(Top)Western blot (bottom) silver staining of Ajuba-His purification fractions. Positive control- 
mammalian cell lysates with Ajuba (not tagged). 6xHis-Ajuba total lysate was loaded in 20ul and 
40ul of volume. All other lanes were loaded with 20ul of fraction. Wash buffer (30mM 
















   
 
  
Figure 23. Affinity purification of His-TRIP6 with Ni-NTA beads. (Top) Western blot (bottom) 
silver staining of TRIP6-His purification fractions.  
 
 
However, this method proved to be inefficient in protein production and time 




AJUBA-RPA INTERACTION USING IN VITRO TNT SYSTEM 
The in vitro transcription/translation system (Promega) contains rabbit reticulocyte 
lysate, and proteins that are necessary to provide the appropriate environment for 
transcription and translation to take place in the reaction mixture. It contains all the 
amino acids but methionine, which can be supplied separately. The methionine 
employed here is radioactively labeled with 35S, thus the proteins produced are 
radioactive and able to be visualized by autoradiography. Recombinant proteins 





Figure 24. Schematic of His-tag pulldown assay with in vitro co-translated proteins. A) Ajuba-
6xHis plasmid (red circle) and RPA subunit plasmid (green circle) were added to the same in 
vitro TnT reaction with 35S-methionine. B) Ni2+ beads are added to the co-translation reaction 








Each of the RPA subunits was cloned into pCMVTnT vector (no tag) separately, 
and Ajuba was cloned into a mammalian CMV N-terminal His tag vector. 6xHis-
Ajuba was co-translated with each of the RPA subunits in the same reaction, and 
then Ni2+ beads were added to pulldown the proteins (Figure 24). If the two 
proteins interact directly, then we would expect the presence of both proteins in the 
















AJUBA DIRECTLY INTERACTS WITH RPA70 
We found strong signal of RPA70 pulled down with His tagged Ajuba (Figure 
25A). We did not observe RPA32 (Figure 25A) or RPA14 pulled down with His-
Ajuba (data not shown). This data suggests that Ajuba directly interacts with 
RPA70 in vitro. In addition, quantitative analysis of the autoradiography showed 
that His-Ajuba can pulldown RPA70 with a signal at least four-fold higher than the 
background seen with RPA32. Ajuba does pull down a very low amount of 
RPA32, and I speculate that this can be largely due to unspecific interaction, but I 
do not exclude the possibility that Ajuba can directly interact with RPA32 though a 
minor interaction surface (Figure 25B). Therefore, I conclude that the association 








Figure 25. Ajuba directly interacts with RPA70 in vitro. A) Autoradiography- His-tag pulldown of 
in vitro translated Ajuba-His with RPA70 or RPA32. B) Quantification of pulldown efficiency 
between RPA70 and RPA32 with Ajuba-His. Pulldown efficiency is calculated by normalizing 
























This finding was intriguing because RPA70 is known to contain the site for the 
assembly of the ATR activating complex. Thus, I sought to dissect the interaction 
between the two proteins by mapping the regions that facilitate the contact. To do 




















AJUBA-RPA70 INTERACTION IS MEDIATED BY C-TERMINAL OB 
FOLDS 
The direct interaction between Ajuba and RPA70 has prompted me to probe the 
regions on both proteins that are responsible for this direct contact. It has been 
shown the N-terminal OB fold (OB fold F) of RPA70 functions as a docking site 
for various DDR checkpoint proteins such as ATRIP, p53, and Rad9 16. OB fold F 
has not been shown to have significant contribution to the protein’s DNA binding 
affinity 43. On the other hand, the three OB folds located at the C-terminus are 
mainly responsible for DNA binding (OB fold A and B) and subunit interaction 
(OB fold C). Further, it was shown that proteins can interact with RPA70 through 
OB fold A and B, such as BLM (Bloom Syndrome helicase), and Rad51 16.  
To identify the region on RPA70 mediating this interaction, we first constructed 
truncation mutants of RPA70, splitting the N-terminal OB fold (OB F) and three of 




Figure 26. Domain maps of RPA70 truncation mutants. Top bar represents the full-length 




We began to study the binding relationship between FL His-Ajuba and RPA70 
mutants by employing in vitro translation system and His-tag pulldown assay. 
Figure 27 shows a strong interaction between FL His-Ajuba and OB ABC of 
RPA70. On the other hand, we did not observe a strong pulldown between OB F 






Figure 27. OB folds ABC exhibit stronger pulldown with Ajuba-His than OB fold F. 
Autoradiography of His-tag pulldown of FL His-Ajuba and A) OB ABC, B) OB F.  
These results show that the C-terminus OB folds of RPA70 mediate the direct interaction 
between the two proteins and that OB F shows minimal contribution to this protein-protein 
contact (Figure 5B).   
 
 
We generated additional truncation mutants of the C-terminal OB fold of RPA70 
to further probe for the region mediating this protein-protein interaction (Figure 
28). We deleted OB fold A from OB ABC to generate OB BC mutant, and 
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pulldown assay showed that the binding with FL His-Ajuba has reduced drastically 
(figure 28A) in contrast to the pulldown of OB ABC (figure 28A). This suggests 
that OB fold A is the main binding region with Ajuba and prompted me to further 







Figure 28. OB fold A is important for direct interaction with Ajuba-His in vitro. Autoradiography 
of His-tag pulldown with FL His-Ajuba and A) OB BC, B) OB ½ ABC, and C) OB FA. Asterisk (*) 




I constructed a mutant harboring half of OB fold A with OB folds B and C and 
assessed the binding with FL His-Ajuba. Although the intensity of OB ½ ABC 
being pulled down is quite low, Figure 28B shows OB ½ ABC can be pulled down 
by FL His-Ajuba with low efficiency. This suggests that a truncated form of OB 
fold A may contain a remaining point of contact with Ajuba, but that the main 
region for the binding resides in the N-terminal portion of OB fold A, which was 
truncated in this construct.  
In order to test this proposition, and to ask whether OB A is sufficient for binding, 
I cloned OB F with the full OB A (OB F+A) to assess whether FL His-Ajuba 
would pull down this fusion protein. Surprisingly, the presence of OB fold A did 
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not increase the amount of mutant pulled down (figure 28C). This suggests that OB 
fold A by itself may not be sufficient to maintain interaction with Ajuba. It is 
possible that the folding of this particular fusion protein used is not presenting a 
proper configuration for binding. Therefore, the structure of OB folds ABC may be 
essential for direct contact between RPA70 and Ajuba, with OB fold A containing 
the actual interaction surface.  
 
 
Figure 29. Pulldown efficiencies of RPA70 mutants by full length His-Ajuba. Pulldown efficiency 
is calculated by normalizing pulldown signals with input and the number of methionine each 
mutant/protein contains.  
 
 
Quantitation of autoradiography revealed that OB ABC alone was sufficient to 
recapitulate the binding with Ajuba compared to FL RPA70 (figure 29). On the 
other hand, OB F has shown to have the least affinity towards FL Ajuba. 
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Truncation of half of OB fold A yielded a 30% decrease in pulldown efficiency 
and omitting the entire OB fold A (OB BC) resulted in a drastic 80% decrease of 
pulldown efficiency. This shows that OB fold A is mostly responsible for the 
contact between Ajuba and RPA70. However, the OB F+A mutant that contains 
the entire OB fold A did exhibit an increase of 15% in pulldown efficiency in 
contrast to OB F alone, although this increase was not found to be statistically 
significant. Overall, OB folds ABC are essential for the interaction between Ajuba 

















LIM DOMAIN 1 OF AJUBA IS REQUIRED FOR EFFICIENT 
INTERACTION WITH RPA70 
I then sought to identify the regions on Ajuba responsible for the Ajuba-RPA70 
interaction. I constructed truncation mutants of Ajuba and cloned into a 
mammalian CMV/NT-6xHis vector (Figure 30). Each of the mutants was co-
translated with FL RPA70 and subjected to affinity pulldown assay. Our lab has 
previously shown that LIM protein TRIP6 directly interacts with another OB fold 
protein POT1 at telomeres through the C-terminal LIM domains of the molecule68. 
  
 
Figure 30. His-tagged Ajuba truncation mutants domains map. 
 
I speculate LIM protein Ajuba directly interacts with the OB fold protein RPA 
through its LIM domains. To test this hypothesis, I generated constructs containing 
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just the PreLIM domain, and, separately, another containing LIM domains 1,2,3. 




Figure 31. LIM domains exhibit stronger pulldown with RPA70 than the PreLIM region. 
Autoradiography of His-tag pulldown with Ajuba mutants A) LIM domains and B) PreLIM region 
and FL RPA70. *All the samples from each figure is from the same experiment. Lanes were 




The autoradiography (figure 31A) showed that LIM domains (LIM-His) are able to 
pulldown FL RPA70, although with weak efficiency. Visually, no significant 
amount of RPA70 being pulled down by the PreLIM region is seen (figure 31B). 
However, when comparing the amount of RPA70 and LIM domains proteins 
pulled down, we observed that a significant amount of LIM domains protein is 
required to pull down the low amount of RPA70 (figure 31A, 33). Complementing 
this data, quantification of PreLIM region pulldown efficiency of FL RPA70 
resembles background levels (figure 33).  
 We considered the possibility that the interacting region of Ajuba with FL RPA70 






Figure 32. Addition of LIM domain 1 to the PreLIM region enhanced pulldown with RPA70 
compared to PreLIM region alone. Autoradiography of His-tag pulldown with Ajuba mutants A) 
PreLIM+LIM1, B) PreLIM+LIM12. *All the samples from each figure is from the same 




To address this, I constructed additional truncation mutants that harbor the PreLIM 
region coupled with one or two LIM domains. If the interacting region was 
abrogated in the previous mutants (LIM domains and PreLIM region), an increase 
of RPA70 in the pulldown would be expected. Indeed, figures 32A and B show 
that the additional LIM domains onto the PreLIM region did enhance the pulldown 
of FL RPA70 compared to PreLIM region or LIM domains alone (figure 33). This 
suggests the first LIM domain of Ajuba plays a crucial role in mediating direct 





Figure 33. Pulldown efficiencies of FL RPA70 by Ajuba mutants. Pulldown efficiency is calculated 
by normalizing pulldown signals with input and the number of methionine each mutant/protein 
contains. 
 
As seen in figure 33, quantitative results support the visual findings of the 
pulldowns. A 16% increase of pulldown efficiency compared between 
PreLIM+LIM1 mutant and LIM domains only was observed. The LIM domains 
displayed two-fold pulldown efficiency increase (20%) in contrast to PreLIM 
region. Interestingly, adding LIM domain 1 onto the PreLIM region significantly 
increased the pulldown efficiency from 10% (PreLIM only) to 36% (PreLIM –
LIM1). Further, an additional LIM domain (PreLIM+LIM12) (38%) did not 
increase the pulldown efficiency of FL RPA70 further compared to adding the first 
LIM domain only (36%). This suggests that the presence of PreLIM region may 
facilitate the direct interaction with RPA70, perhaps through the maintenance of 
proper protein folding. 
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Collectively, these data entail the PreLIM region along with the LIM domain 1 are 
important for Ajuba-RPA70 contact. However, I was not able to narrow down a 
domain with similar efficiency of pull down than the full length of Ajuba, but these 
results do point to an important domain containing the first LIM domain of the 
















CHAPTER SUMMARY/ DISCUSSION: 
My data describes that the LIM domains of Ajuba are essential for the interaction 
with RPA70. In particular, addition of the first LIM domain (PreLIM-LIM1, 36%) 
to the PreLIM region increased the pulldown efficiency by three-fold compared to 
PreLIM region (10%) (figure 33). These finding is in agreement with previous 
publication that describes the LIM domains of TRIP6 mediate direct contact with 
the ssDNA binding OB folds of POT1 68. I speculate that the PreLIM region 
facilitates the direct interaction through contributing to proper protein folding of 
Ajuba. Another possibility is that the PreLIM region with LIM domain 1 mediates 
this direct contact with RPA70. Moreover, it is possible that additional folding 
issues prevents full activity of the PreLIM-LIM1 truncation mutant in its binding 
to RPA70, thus resulting in decrease of pulldown efficiency.  
In addition, it is intriguing that Ajuba directly contacts the major ssDNA-binding 
domain of RPA70, OB fold A. Although we do not exclude OB fold B also 
contribute to the interaction, we conclude that OB fold A is the major interface for 
direct interaction with Ajuba. Overall, these findings uncover the domains that 
mediate direct interaction between RPA70 and Ajuba. I speculate that the two 




Figure 34. Central region of Ajuba (including LIM domain 1) and OB fold A of RPA70 mediate the 
direct interaction between the two proteins in vitro. Linear depiction of PreLIM region and LIM 
domains in Ajuba, OB folds in RPA subunits. Bracket and bold black arrow represent the regions 
responsible for direct interaction between Ajuba and RPA70. Numbers represent the amino 
acid positions of each domain. Arrows indicate the position truncated in mutants. Blue arrows 
depict interactions between RPA subunits OB folds. Circle with P on RPA32 indicates multiple 
phosphorylation sites on RPA32.  
 
 
An extension of these studies would involve the test of these ideas by generating 
point mutations instead of truncations, in both the RPA70 and Ajuba cDNAs to pin 














CHAPTER 6: DISCUSSION & CONCLUSION 
 
Ajuba is pivotal for unperturbed cell cycle progression, since the depletion of 
Ajuba lead to cell cycle delay and induce DNA damage foci 73 (Figure 10). During 
normal cell cycle, Ajuba is found to exhibit nuclear localization (HTC75 cells, 
Figure 14), and colocalize with the RPA complex in the nucleus of HTC75 and 
IMR90 cells (figures 11 & 12). I found the retention of Ajuba in the nucleus and 
colocalization events are enhanced by S phase synchronization by dT block and 
release, or by leptomycin B treatment (Figures 13, 14, 15, and table 3). Ajuba is 
also found at a subset of replication sites during S phase (PCNA) (Figure 16). 
These data support the role that Ajuba is essential for S phase progression. It was 
shown that RPA complex colocalizes with replication centers during S phase 103. I 
would speculate that Ajuba interacts with chromatin bound RPA, though not 
explicitly demonstrated here. It was published that the RPA complex exists in the 
nucleoplasmic fraction and chromatin fraction, and treatment with mild detergent 
(Triton-X 100) removes the nucleoplasmic portion of RPA, retaining the chromatin 
bound fraction 103. In addition, extensive work has established the role of the RPA 
complex in replication sites 21. Thus, I propose that Ajuba interacts with RPA to 
inhibit local DDR at replication forks, and possibly also at endogenous sites of 
DNA damage that spontaneously form during S phase.  
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Once Ajuba is depleted in the cell, it allows DDR factors to be recruited to the 
RPA-ssDNA at a subset of replication forks that triggered a global activation of 
ATR response. Whether Ajuba depletion activates ATM response has not been 
fully investigated, although no activation of Chk2 was ever observed (DL and SK, 
unpublished). I hypothesize that the subset of Ajuba associated replication sites at 
possibly difficult to replicate regions or common fragile sites. However, this notion 
has not yet been tested and remains speculative.  
The reduction of Ajuba-RPA interaction upon replication stress (figures 17, and 
table 4) entails that the dissociation of Ajuba-RPA interaction is necessary for 
DDR. Both cell lines showed similar percentages of cells with nuclear Ajuba 
signals with and without HU treatment (table 4), suggesting Ajuba probably exert 
the same function in both cell lines to repress unwanted DDR. Therefore, the 
effects seen appear to be indicative of an important cellular pathway, and do not 
pertain to a tumor phenotype. The apparent lack of Ajuba signal in the nucleus 
during replication stress (HU) underscores the point established from previous 
works that Ajuba functions as a DDR antagonist (figure 18 & 19). The lower MW 
Ajuba band found in chromatin bound fraction in unperturbed cells most likely 
represent an isoform of Ajuba or a unphosphorylated species of the protein. The 
former proposition is supported by isoform 3 of Ajuba (NCBI), which displays 
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similar MW shown on the Western blot but contains a distinct C-terminus. Further 
confirmation is needed to ensure whether the lower MW band represent isoform 3.  
The direct interaction between Ajuba and RPA70 (figures 25, 27, 28, 29) 
complements the previous finding of direct contact between LIM protein and OB 
fold protein 67,68. Ajuba shares the interacting domain on RPA70 with proteins 
implicate in DNA repair such as Rad51 104. One model could be that Ajuba 
modulates RPA70 ssDNA-binding affinity and implicate in DNA repair pathways. 
It has been shown that reconstitution of RPA coated-ssDNA activates ATR 
response in Xenopus egg extracts 105, highlighting the importance of RPA-ssDNA 
structures in DDR. I hypothesize that in order to prevent the accumulation of RPA 
bound ssDNA at the replication fork, Ajuba may increase the “off” rate of RPA on 
ssDNA to maintain a minimal amount of RPA at the replication site to evade 
unnecessary ATR activation.  
On the other hand, the central region of Ajuba was shown to mediate this contact 
(figures 31, 32, 33). This region was previously uncharacterized and did not fit my 
initial hypothesis of LIM domains being the mediator to directly contact OB fold 
proteins. The significance of this region in preventing DDR remains to be 
elucidated. These findings contribute to the role of LIM proteins in maintenance of 
genome integrity and regulation of DDR.  
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The data presented here have added important information to our previous model 





Figure 35. Proposed model of Ajuba in the ATR pathway. A) General depiction of the ATR 
pathway activation. B) During unperturbed cell cycle, Ajuba directly interacts with RPA70 to 
prevent unscheduled ATR activation. Question marks represent unknown mechanisms as to 
whether this interaction inhibits the phosphorylation of ATR-ATRIP, or RPA, or the recruitment 





I would propose that Ajuba exerts its function at the initiating stage of the ATR 
pathway, when RPA-ssDNA is present in the cell (figure 35A). Specifically, Ajuba 
directly binds to RPA70 (figure 35B). This interaction may be inhibiting the 
phosphorylation of RPA32 or ATR-ATRIP, or it may prevent the recruitment of 
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argue this direct interaction takes place during S phase of the cell cycle, to prevent 
unscheduled local ATR response at the replication fork. This leaves an important 
question unanswered: how does the response get back to the uninduced state after 
activation? One model would include RPA32 phosphorylation as the primary event 
in this context: spontaneous de-phosphorylation after repair would allow for the re-
association of Ajuba with RPA, allowing for the resumption of ATR inhibition and 
termination of the signaling. Ajuba could therefore be important in two aspects of 
the pathway: initial induction at the local sites of damage, as well as resumption of 
the uninduced state during S phase. In summary, the direct association between 





Figure 36. The most frequent Ajuba alterations across different types of cancer. Ajuba 
expression is amplified in approximately 17% of neuroendocrine prostate cancer (NEPC, 1st 
column) and around 6% of all prostate cancers that were examined. Ajuba is frequently 
mutated in Head and Neck Small Cell Carcinoma (HNSCC), 6.3% and 5.7% respectively (2nd and 
3rd column). Each color bar indicates distinct types of alteration of Ajuba. Cancer type: light blue 
(neuroendocrine prostate cancer), burgundy (Head and Neck Small Cell Carcinoma), purple 










Figure 36 shows the most common alterations that were characterized in different 
cancer types. Importantly, Ajuba expression is found to be amplified in 
neuroendocrine prostate cancer. Specifically, around 17 % of exhibited high Ajuba 
expression. Further, Ajuba is upregulated in pancreatic cancer, ovarian cancer and 
lung adenocarcinomas. Thus, in addition to my findings presented here, Ajuba may 
contribute to cancer cell proliferation and tumorigenesis through repression of 
ATR signaling pathway.  
On the other hand, Ajuba is found to be frequently mutated in Head and Neck 
Small Cell Carcinoma (HNSCC). As seen in Figure 37, Ajuba is often altered in 
the mid-region that includes LIM domain 1. In addition, most of the mutations 
identified are either missense or truncations.  
 
Figure 37. Mapping of Ajuba mutations found in various cancers. Each post color resembles the 
type of mutation found at that specific site as indicated below the domain map. *Image 





This suggests that Ajuba mutations can promote cancer in certain cell types. Based 
on the findings in this thesis, Ajuba truncation can lead to defects in DNA 
replication or alterations in RPA metabolism in the cell which can cause genome 
instability. Thus, overexpression and mutation of Ajuba can contribute to 
tumorigenesis in specific cell types.  
Collectively, the findings of this project contribute to the understanding of the 
“double lives” of Ajuba in the cytoplasm and nucleus. In other words, cytoplasmic 
Ajuba functions to associate with focal adhesion sites and implicates in cell 
migration, while nuclear Ajuba is involved in the repression of DNA damage 
response during S phase. Further, the shuttling of Ajuba out of the nucleus is 
speculated to aid efficient ATR activation. It is possible that Ajuba can exert 
distinct functions by using different regions (i.e. PreLIM, LIM domains) to 
mediate protein interactions. However, functional separation of Ajuba’s protein 








CHAPTER 7: FURTURE DIRECTION 
A major point that was not addressed in this project was whether Ajuba interacts 
with RPA bound to ssDNA. The investigation was hampered by difficulty in 
protein purification using the E. coli system, thus not being able to quantitate and 
control the amount of proteins that will be employed in electro-mobility shift 
assay. Thus, it will be important to assess whether Ajuba can influence the binding 
affinity of RPA for the DNA. This remains to be one of the on-going works in the 
lab to directly investigate the relationship between Ajuba and RPA complex on 
ssDNA.  
The phosphorylation status of RPA32 has been shown to modulate RPA complex 
recruitment and function 25,27,48. Although not explored here, I hypothesize that 
Ajuba may play a role in preventing DDR induced phosphorylation of RPA32. 
During replication stress, DDR induced phosphorylation of RPA32 can potentially 
decrease the complex affinity for Ajuba, and thus leading to full activation of ATR. 
On the other hand, Ajuba may function to dampen local ATR response after the 
damage has been repaired through interacting with RPA70. Further investigation is 
needed to confirm if DDR induced phosphorylated species of RPA complex 
exhibit lower affinity for Ajuba and if Ajuba is only present at newly repaired 
damage sites.  
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Additionally, the RPA70 interacting interface on Ajuba does not exactly coincide 
with the POT1 interacting domains identified on TRIP6; although LIM domains is 
the major contributor to the direct interaction for Ajuba-RPA70, and TRIP6-POT1. 
A well-defined region of interaction on Ajuba could not be identified through 
truncation mutants. The interacting domains mapped here provide the framework 
for generating point mutants within these regions, which will provide more precise 
information about the interaction between Ajuba and RPA70.  
Additional experiments showed that Ajuba does not directly interact with POT1 
(data not shown). I suspect that this is due to the difference in tertiary structure of 
the ssDNA-binding OB folds on POT1 and RPA70, which also mediate direct 
interaction with LIM proteins. POT1 N-terminal OB folds exhibit a “kink” binding 
to ssDNA, while RPA70 OB folds A and B display as a linear groove. This 
difference may contribute to distinct interacting partners.  
It was shown that TRIP6, LPP, but not Zyxin were found localized at telomeres 67, 
this entails a differential local recruitment of LIM proteins to sub-nuclear regions. 
However, the possibility that TRIP6 can interact with RPA is not excluded here 
due to the transient presence of RPA at the telomeres during S phase 30. 
Collectively, I propose that TRIP6 functions at the telomeres and Ajuba functions 
throughout other genomic regions to prevent unwanted DDR, potentially 
displaying the same paradigm in their associations and functions. Further 
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examination will be needed to confirm the two LIM proteins’ roles at sub-genomic 
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